Inditex Re-enters Venezuelan Market with Zara Store Opening 
Hybe Accuses ADOR Subsidiary’s CEO of Breach of Trust 
Toyota Teams with Tencent, Nissan Joins Forces with Baidu in China AI Drive 
Mercedes-Benz to Release Luxury Electric Van in China 
GS25 Launches Limited-Edition Makgeolli ‘Seoul Silver’ in Korea 
The Future of Gold Trading: Technological Advances and Market Predictions in the Philippines 
Binance Reassures Filipino Users Amid SEC App Removal Request, Urges Balanced Review by Google and Apple 
Nestle Reports Sales Dip Amid Price Hikes 
PUMA and Scuderia Ferrari HP Unveil Miami Limited Edition Collection 
PUMA x KIDSUPER Collaboration Elevates Basketball Fashion with New MB.03 Shoe 
Juventus Partners with Two Circles in Bid to Globalize Brand and Enhance Partnerships 
Toyota Motor Launches Trial for EV Pickups in Thailand 
Ferrari F1 Announces Multi-Year Partnership with HP as Title Sponsor 
Nestlé Crushes Two Million Perrier Drinks Due to Contamination 
Hertz to Offload 30K EVs This Year, Deepens Cuts Amid Mounting Fleet Losses 
NEW YORK, June 23, 2017 -- Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Roche Holding AG (OTCQX:RHHBY) from March 2, 2017 through June 5, 2017, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Roche investors under the federal securities laws.
To join the Roche class action, go to http://www.rosenlegal.com/cases-1140.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) the combination of Perjeta and Herceptin is only marginally more effective than Herceptin alone in preventing breast cancer; and (2) as a result, Defendants’ statements about the Company’s business, operations and prospects were materially false and misleading and/or lacked a reasonable bases at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 7, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1140.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
